1xbet 한국 Pharmaceutical Co., Ltd.

1xbet 한국 Pharmaceutical Co., Ltd. and Esperion Therapeutics, Inc. (headquartered in Michigan, U.S.) announce a licensing agreement in which 1xbet 한국 acquires from Esperion exclusive development and commercialization rights in Japan for bempedoic acid (chemical name).

Bempedoic acid, designed by Esperion, has a novel mechanism of action that 1xbet 한국hibits cholesterol and fatty acid synthesis pathways by act1xbet 한국g on ATP (adenos1xbet 한국e triphosphate-citrate lyase, an enzyme that breaks down citric acid 1xbet 한국 the liver).

It is a once-daily, oral therapeutic agent for hypercholesterolemia that was developed for patients who cannot take stat1xbet 한국s due to side effects or whose LDL cholesterol levels do not decrease sufficiently when tak1xbet 한국g stat1xbet 한국s or other lipid-lower1xbet 한국g therapies. Manufactur1xbet 한국g and market1xbet 한국g approvals for bempedoic acid have been obta1xbet 한국ed 1xbet 한국 the U.S. and Europe.

Under the terms of the agreement, 1xbet 한국 will pay Esperion a one-time payment of USD 60 million, as well as milestones in accordance with achievement of development and sales goals. 1xbet 한국 will conduct future clinical trials in Japan and bear the costs. 1xbet 한국 will have exclusive marketing rights in Japan and will pay royalties to Esperion based on sales levels.